Bassam Choudhry
Pulmonary Disease · Tucson, AZNPI 1477833028
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), food and beverage and education — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 65.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $925 and has fallen 98.4% since, to $15 in 2022. That places this record below the midpoint for pulmonary disease clinicians in AZ, where the typical reported total is $2,499.
Across 45 payments — averaging $35.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Astellas Pharma US Inc$165
- GSK$161
- Roche Diagnostics Corporation$50
- La Jolla Pharmaceutical Company$36
- Grifols USA, LLC$29
- plus $104 from 6 others
What the payments were for
- Speaking & faculty fees$75047%
- Food & beverage$67142%
- Education$17111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $1,047 |
| Astellas Pharma US Inc | 3 | $165 |
| GSK | 10 | $161 |
| Roche Diagnostics Corporation | 1 | $50 |
| La Jolla Pharmaceutical Company | 2 | $36 |
| Grifols USA, LLC | 2 | $29 |
| Philips North America LLC | 1 | $26 |
| Shire North American Group Inc | 1 | $17 |
| AbbVie | 1 | $17 |
| Novartis | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,593 in reported general payments places this provider in the 40th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,907 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 55 | $585 |
| Doxycycline Hyclate | 29 | $348 |
| Methylprednisolone | 39 | $307 |
| Cefdinir | 11 | $197 |
| Cephalexin | 12 | $103 |
| Levofloxacin | 30 | $102 |
| Amlodipine Besylate | 27 | $100 |
| Metronidazole | 18 | $86 |
| Hydralazine Hcl | 12 | $82 |
| Metoprolol Succinate | 16 | $68 |
| Pantoprazole Sodium | 14 | $67 |
| Atorvastatin Calcium | 15 | $66 |
| Ciprofloxacin Hcl | 19 | $63 |
| Tramadol Hcl | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Tucson
- Abhinav MittalTucson$570K
- Sachin ChaudharyTucson$90K
- Billie BixbyTucson$35K
- Todd LocherTucson$25K
- Ravi ChandranTucson$13K
- James KneplerTucson$12K
- Ubair AhmedTucson$10K
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.